Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia

Jennifer R. Brown*, Wael A. Harb, Brian T. Hill, Janice Gabrilove, Jeff P. Sharman, Marshall T. Schreeder, Paul M. Barr, James M. Foran, Thomas P. Miller, Jan A. Burger, Kevin R. Kelly, Daruka Mahadevan, Shuo Ma, Yan Li, Daniel W. Pierce, Evelyn Barnett, Jeffrey Marine, Monika Miranda, Ada Azaryan, Xujie YuPilar Nava-Parada, Jay Mei, Thomas J. Kipps

*Corresponding author for this work

Research output: Contribution to journalLetter

26 Scopus citations
Original languageEnglish (US)
Pages (from-to)e295-e298
JournalHaematologica
Volume101
Issue number7
DOIs
StatePublished - Jan 1 2016

Keywords

  • BTK inhibitors
  • CC-292
  • Chronic lymphocytic leukemia
  • Refractory
  • Relapsed
  • Single-agent
  • Small lymphocytic lymphoma

ASJC Scopus subject areas

  • Hematology

Cite this

Brown, J. R., Harb, W. A., Hill, B. T., Gabrilove, J., Sharman, J. P., Schreeder, M. T., Barr, P. M., Foran, J. M., Miller, T. P., Burger, J. A., Kelly, K. R., Mahadevan, D., Ma, S., Li, Y., Pierce, D. W., Barnett, E., Marine, J., Miranda, M., Azaryan, A., ... Kipps, T. J. (2016). Phase I study of single-agent CC-292, a highly selective bruton’s tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica, 101(7), e295-e298. https://doi.org/10.3324/haematol.2015.140806